Connect your AI

Veracyte VCYT Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Guardant HealthGH

$3.65M+375%

Natera, Inc.NTRA

$3.86M+610%

Bio-Rad LaboratoriesBIO

$3.4M-20.9%

RevvityRVTY

$5.44M+107%

Quest DiagnosticsDGX

$65M+124%

Agilent TechnologiesA

$1M0.0%

Other financials

Income statement

Revenue$139.1M+21.5%

Gross profit$101.2M+27.2%

Operating income$22.6M+680%

Net income$28.7M+307%

EPS (diluted)$0.35+289%

Balance sheet

Cash & equivalents$264.8M+41.0%

Total debt$39.3M-22.1%

Total equity$1.3B+12.5%

Total assets$1.4B+9.2%

Cash flow

Operating cash flow$35.2M+557%

CapEx$3.0M+62.8%

Free cash flow$32.3M+810%

Valuation

Market cap$4.29B+10.7%

Profitability

Gross margin70.9%+2.9pp

Operating margin14.3%+9.2pp

Net margin16.2%+9.1pp

FCF margin28.7%+11.7pp

Returns & leverage

Return on equity6.9%+4.1pp

Debt / equity0×0.0×

Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Veracyte's stock issuance proceeds?: Veracyte (VCYT) reported stock issuance proceeds of $2.74M in Q1 2026.
How has Veracyte's stock issuance proceeds changed year-over-year?: Veracyte's stock issuance proceeds decreased by 7.8% year-over-year, from $2.97M to $2.74M.
What is the long-term trend for Veracyte's stock issuance proceeds?: Over 4 years (2021 to 2025), Veracyte's stock issuance proceeds has grown at a 5.1% compound annual growth rate (CAGR), from $11.53M to $14.08M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.